Highlights

• A new brain cancer imaging drug has secured U.S. FDA approval.
• The approval could improve the ability to identify glioma progression separately from treatment-related changes.
• Shares climbed 8.23% to AU$16.960 following the announcement.

FDA Decision Opens a New Chapter

Telix Pharmaceuticals Limited (ASX: TLX) has secured an important regulatory win after the U.S. FDA granted approval for its New Drug Application covering Pixclara® (floretyrosine F 18, or 18F-FET). The announcement was made on 14 September 2026, with the approval covering Pixclara as a positron emission tomography (PET) imaging drug for gliomas, a form of brain cancer. According to the company, Pixclara is the first FDA-approved FET-PET imaging drug for glioma, potentially opening broader access to this imaging approach in the United States.

Addressing a Critical Diagnostic Challenge

Pixclara is designed to help differentiate recurrent or progressive glioma from changes caused by previous treatment. The product can be used alongside other diagnostic evaluations in both adult and pediatric patients aged one month and older. FET-PET imaging is already recommended by international clinical practice guidelines, including the NCCN Guidelines. However, Telix noted that an FDA-approved product for this application had not previously been available in the U.S. The opportunity is significant, with approximately 24,000 new glioma cases diagnosed annually in the United States, according to the announcement.

Share Price Gains 8.23%

The regulatory development was accompanied by a strong move in Telix's share price. TLX was trading at AU$16.960, up AU$1.290 or 8.23%, highlighting positive investor reaction to the FDA decision. The approval also strengthens Telix's Precision Medicine business and adds another commercial product to its growing radiopharmaceutical portfolio.

Expanding the Precision Medicine Portfolio

Pixclara joins Telix's existing diagnostic franchise, which includes Illuccix® and Gozellix®, while the company continues advancing several investigational therapeutic programs targeting cancers including prostate, brain and kidney cancer. The company said the FDA decision could provide physicians with greater certainty in diagnosis and treatment planning, while expanding access to FET-PET imaging in the U.S.

Conclusion

The 14 September 2026 FDA approval of Pixclara represents an important step for Telix Pharmaceuticals in the brain cancer diagnostics market. With a first-of-its-kind U.S. approval, an established role for FET-PET imaging in international guidelines and a strong share-price response, the development could further reinforce Telix's position in precision radiopharmaceutical medicine.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au